Puricore remains at an interesting juncture in its development as it transitions to a fully fledged drug development company based on leveraging its proprietary immunomodulatory technology to develop novel, topical treatments for inflammatory diseases. The Supermarket Retail division, now deemed non-core, delivered a strong revenue performance but still requires investment support. As such options are being considered that could drive further growth and generate shareholder value.
25 Mar 2016
FY15 Prelims
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY15 Prelims
Realm Therapeutics (RLM:LON) | 0 0 0.3% | Mkt Cap: 57.1m
- Published:
25 Mar 2016 -
Author:
Chris Glasper -
Pages:
3
Puricore remains at an interesting juncture in its development as it transitions to a fully fledged drug development company based on leveraging its proprietary immunomodulatory technology to develop novel, topical treatments for inflammatory diseases. The Supermarket Retail division, now deemed non-core, delivered a strong revenue performance but still requires investment support. As such options are being considered that could drive further growth and generate shareholder value.